Clinical Trial Update: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) [Phase 1, Phase 2]

View source ↗

Summary

Clinical Trial Update on the ALPHA2 Phase 1/2 study evaluating ALLO-501A anti-CD19 allogeneic CAR T cells in adults with relapsed/refractory diffuse large B-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• ALLO-501A (anti-CD19 allogeneic CAR T cells)

Snippet

Sponsor: Allogene Therapeutics | Conditions: Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING